Details

Autor(en) / Beteiligte

• Chan, Anthony T. C.
• Leung, S. F.
• Ngan, Roger K. C.
• Teo, Peter M. L.
• Lau, W. H.
• Kwan, W. H.
• Hui, Edwin P.
• Yiu, H. Y.
• Yeo, Winnie
• Cheung, F. Y.
• Yu, K. H.
• Chiu, K. W.
• Chan, D. T.
• Mok, Tony S. K.
• Yau, Stephen
• Yuen, K. T.
• Mo, Frankie K. F.
• Lai, Maria M. P.
• Ma, Brigette B. Y.
• Kam, Michael K. M.
• Leung, Thomas W. T.
• Johnson, Philip J.
• Choi, Peter H. K.
• Zee, Benny C. Y.

Titel

Overall Survival After Concurrent Cisplatin–Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma

Ist Teil von

• JNCI : Journal of the National Cancer Institute, 2005-04, Vol.97 (7), p.536-539

Ort / Verlag

Cary, NC: Oxford University Press

Erscheinungsjahr

2005

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• This phase III randomized study compared concurrent cisplatin–radiotherapy (CRT) versus radiotherapy (RT) alone in patients with locoregionally advanced nasopharyngeal carcinoma. A total of 350 patients were randomly assigned to receive external RT alone or concurrently with cisplatin at a dosage of 40 mg/m2 weekly. The primary endpoint was overall survival, and the median follow-up was 5.5 years. The 5-year overall survival was 58.6% (95% confidence interval [CI] = 50.9% to 66.2%) for the RT arm and 70.3% (95% CI = 63.4% to 77.3%) for the CRT arm. In Cox regression analysis adjusted for T stage, age, and overall stage, the difference in overall survival was statistically significantly in favor of concurrent CRT (P = .049, hazard ratio [HR] = 0.71 [95% CI = 0.5 to 1.0]). Subgroup analysis demonstrated that there was no difference between overall survival in the arms for T1/T2 stage (P = .74, HR = 0.93 [95% CI = 0.59 to 1.4]), whereas there was a difference between the arms for T3/T4 stage (P = .013, HR = 0.51 [95% CI = 0.3 to 0.88]), favoring the CRT arm. The regimen of weekly concurrent CRT is a promising standard treatment strategy for locoregionally advanced nasopharyngeal carcinoma patients.